Yumanity Therapeutics, Inc. (YMTX)

Chinese stocks are rallying on Monday as investors get more hopeful news of the country loosening its Covid-19 restrictions. Over the weekend, China reportedly let go of some of its restrictions on certain cities affected by the pandemic.

Yumanity Therapeutics (NASDAQ: YMTX ) stock is rocketing higher on Monday after the clinical-stage biopharmaceutical company announced a special dividend. According to a press release from the company, this special dividend will range in price from $1.34 to $1.43 per share.

Check these penny stocks out for your watchlist right now The post Best Penny Stocks to Buy That Exploded Today? 3 to Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Yumanity Therapeutics (YMTX) stock is rocketing higher on Monday after announcing two definitive agreements. including a merger.

Yumanity Therapeutics Inc (NASDAQ: YMTX) has agreed to sell its lead clinical-stage product candidate, YTX-7739, and discovery-stage neuroscience candidates to Janssen Pharmaceutica NV, a unit of Johnson & Johnson (NYSE: JNJ) for $26 million. Yumanity plans to.

Yumanity (YMTX) delivered earnings and revenue surprises of -21.57% and 31.80%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

BOSTON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that Richard Peters, M.D., Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright BioConnect Conference, being held virtually January 10-13, 2022.

BOSTON, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that Richard Peters, M.D., Ph.D., President and Chief Executive Officer, will be presenting at the following investor conferences in November. He will discuss the results of the recently completed Phase 1b study of YTX-7739 in patients with Parkinson's disease and the development strategy going forward.

Yumanity Therapeutics Inc (NASDAQ: YMTX) reported topline data from Phase 1b trial of its lead product candidate, YTX-7739, for mild-to-moderate Parkinson's disease. The study achieved its primary endpoints.

BOSTON, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced the grant to an employee of non-statutory stock options for the purchase of up to an aggregate of 4,000 shares of Yumanity's common stock. The options will vest over four years, with 25 percent of the shares vesting on the first anniversary of the employee's new hire date and the remainder vesting in equal monthly installments over the following three years. The options will have an exercise price of $10.48 per share, which is equal to the closing price of Yumanity's common stock on October 1, 2021, the grant date for the stock options, have a ten-year term and will be subject to the terms and conditions of the Yumanity Therapeutics, Inc. 2021 Inducement Plan and the terms and conditions of a stock option agreement covering the grant. The stock options were granted as inducements material to the employee's entering into employment with Yumanity Therapeutics in accordance with Nasdaq Listing Rule 5635(c)(4).

BOSTON, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced the grant to one new employee of a non-statutory stock option for the purchase of up to an aggregate of 30,000 shares of Yumanity's common stock. The option will vest over four years, with 25 percent of the shares vesting on the first anniversary of the employee's new hire date and the remainder vesting in equal monthly installments over the following three years. The option has an exercise price of $10.88 per share, which is equal to the closing price of Yumanity's common stock on September 1, 2021, the grant date for the stock option, has a ten-year term and is subject to the terms and conditions of the Yumanity Therapeutics, Inc. 2021 Inducement Plan and a stock option agreement covering the grant. The stock option was granted as an inducement material to the employee entering into employment with Yumanity Therapeutics in accordance with Nasdaq Listing Rule 5635(c)(4).

YTX-7739 shown to inhibit its novel target in healthy volunteers at levels consistent with improved motor function in an animal model of Parkinson's disease

BOSTON, April 28, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that Richard Peters, M.D., Ph.D., President and Chief Executive Officer, will present at the 2021 B. Riley Securities' Neuroscience Conference.

YTX-7739 is Yumanity's lead product candidate in clinical development for the treatment of Parkinson's disease YTX-7739 is Yumanity's lead product candidate in clinical development for the treatment of Parkinson's disease

Yumanity Therapeutics (NASDAQ: YMTX) has announced results from preclinical studies of YTX-7739 in glioblastoma multiforme (GBM). Researchers at the Massachusetts General Hospital conducted the study.

Closed $33.6 million PIPE in conjunction with the completion of reverse merger with Proteostasis Therapeutics; commenced trading on the Nasdaq Capital Market under the ticker symbol “YMTX”